Quantcast

Latest Northwest Biotherapeutics Inc. Stories

2014-08-19 16:29:08

Funding To Increase Manufacturing Capacity for Ramp-Up of Programs BETHESDA, Md., Aug. 19, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the $17.5 million convertible note offering announced last Thursday, August 14, 2014, has closed. The three-year notes have a 5% interest rate and are convertible at $7.30 per share of common stock. The...

2014-08-14 12:27:56

Convertible at $7.30 Per Share; Will Fund New Manufacturing Capacity in Europe BETHESDA, Md., Aug. 14, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio") today announced the pricing of $17.5 million aggregate principal amount of its unsecured convertible notes (the "Notes") in a private placement. The Notes are initially convertible at $7.30 per share, a 10% premium above the closing market price of $6.64 per share on August 13, 2014. NW Bio plans to...

2014-08-13 08:29:58

Phase III Trial Is Alive And Well; "Hint Of Failure" A Complete Fabrication; No Interim Analysis of Efficacy Done; 55 Patients' Positive Data Independently Collected. BETHESDA, Md., Aug. 13, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today corrected ongoing false claims by Adam Feuerstein published on the TheStreet.com about the Company's Phase III trial of DCVax-L...

2014-08-11 08:29:18

Trial Progressing On Track; BETHESDA, Md., Aug. 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced an update about the Company's Phase III clinical trial of DCVax®-L for Glioblastoma multiforme (GBM) brain cancer in conjunction with the Company's separate announcement today about certain changes to the Phase III trial. The update from the Company...

2014-08-11 08:29:14

Important New Variable Covered. Threshold for Meeting Primary Endpoint Lowered. BETHESDA, Md., Aug. 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that, following a 9-month process of regulatory submissions and reviews by regulators in the US, UK and Germany, it has obtained regulatory approvals to make certain enhancements to its ongoing...

2014-07-16 08:28:30

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway BETHESDA, Md., July 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase II...

2014-07-09 20:22:36

NEW YORK, July 9, 2014 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Northwest Biotherapeutics, Inc. ("Northwest Bio" or the "Company") (NasdaqCM: NWBO) in connection with possible breaches of federal securities laws. The investigation regards concerns that the Company made misleading statements regarding its clinical trial for DC-Vax Direct, its experimental cancer vaccine. http://photos.prnewswire.com/prnvar/20120409/MM84375LOGO To get more information, click here:...

2014-06-20 08:23:49

Company Refutes Latest Feuerstein False Headline and Attacks BETHESDA, Md., June 20, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted Adam Feuerstein's latest false headline and attack on the Company, and reaffirmed the Company's recent interim data announcements from its Phase I/II clinical trial of DCVax-Direct for all inoperable solid tumors....

2014-06-16 08:29:01

BETHESDA, Md., June 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been added to two prestigious Russell Indexes: the Russell Global and the Russell 3,000 Indexes. The preliminary announcement was made on Saturday, June 14, 2014, and becomes effective on June 27, 2014. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO The...

2014-06-04 12:29:56

BETHESDA, Md., June 4, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the Jefferies 2014 Global Healthcare Conference, which is being held in New York. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO NW Bio's presentation will take place on Wednesday, June 4, at 2:00 p.m. EDT in Ballroom 5 at the...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related